UNIVERSITY^{OF} BIRMINGHAM

University of Birmingham Research at Birmingham

Sunitinib treatment enhances metastasis of innately drug resistant breast tumors

Wragg, Joseph; Heath, Victoria; Bicknell, Roy

DOI:

10.1158/0008-5472.CAN-16-1982

License:

None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):

Wragg, J, Heath, V & Bicknell, R 2017, 'Sunitinib treatment enhances metastasis of innately drug resistant breast tumors', *Cancer Research*, vol. 77, no. 4, pp. 1008-1020. https://doi.org/10.1158/0008-5472.CAN-16-1982

Link to publication on Research at Birmingham portal

Publisher Rights Statement:

http://cancerres.aacrjournals.org/content/77/4/1008

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)

•Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.


When citing, please reference the published version.

Take down policy


While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.


If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 19. Apr. 2024



Supplementary figure 1. Sunitinib resistance inheritance. Tumour cells were isolated from 4T1 tumours displaying acquired (responsive cohort) or innate (non-responsive cohort) resistance to sunitinib treatment *in vivo* and cultured for 2 weeks. A, tumour growth curves of the selected tumours from each cohort. 2.5 x 10^5 tumour cells from each culture along with treatment naïve 4T1 tumour cells were innoculated into Balb/c mice and the tumours allowed to grow to 600 mm³ with or without 40 mg/Kg sunitinib treatment. B, tumour growth curves (mean \pm SEM) and Kaplan-meier plots for each inoculation, split into Untreated (green), Responsive (blue) and Non-responsive (red) cohorts. N-numbers as shown.







Supplementary figure 2: Endothelial isolation from murine breast tumours. A, workflow of the main steps involved in the murine endothelial cell isolation proceedure. B, RTqPCR for markers of leukocytes (CD11b), macrophages (CD68), epithelium (EPCAM), smooth muscle (PDGFRA) and endothelium (PECAM) in the endothelial isolates (EC) from responsive, untreated and non-responsive tumours (n=4,4,4) standardised to β -actin (a house keeping gene) and normalised for marker expression to matched bulk tissue. Mean fold change of marker expression between the endothelial and bulk fraction is shown \pm SEM.

Supplementary Figure 2:

Tumour growth curves for samples used in 1300 mm³ microarray analysis



Tumour growth curves for 9 days and 600 mm³ microarrays



Supplementary figure 3: Representative tumours from the non-responsive (square), responsive (circle) and untreated (cross) group at each time period, were subjected to microarray transcriptomic analysis. Graphs showing individual tumour growth data points and mean tumour size of the selected tumours over the period of the experiment. N-numbers for each experiment are shown.